1. The respiratory system. National Heart, Lung, and Blood Institute website. Accessed .
  2. What happens when you breathe? National Heart, Lung, and Blood Institute website. Accessed .
  3. Johns Hopkins Cystic Fibrosis Center. Science of CF: CFTR: Function. Accessed .
  4. Basics of lung care. Cystic Fibrosis Foundation website. Accessed .
  5. The Cystic Fibrosis Center at Stanford. The basics of CF. Accessed .
  6. Cystic fibrosis. National Heart, Lung, and Blood Institute website. Accessed .
  7. Cystic Fibrosis Foundation Patient Registry. 2016 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2017. Accessed .
  8. Pritt B, O’Brien L, Winn, Washington. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128:32-34.
  9. Harrison JJ, Turner RJ, Marques LLR, Ceri H. Biofilms: A new understanding of these microbial communities is driving a revolution that may transform the science of microbiology. Am Sci. 2005;93:508–515.
  10. Cystic Fibrosis. US National Library of Medicine website. Genetics Home Reference. Accessed .
  11. Cunningham JC, Taussig, LM. Respiratory system. In: An Introduction to Cystic Fibrosis For Patients and Their Families. 6th ed. Cystic Fibrosis Foundation; 2013:41-58.
  12. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest. 2009;135:1223-1232.
  13. Data on file, Gilead Sciences, Inc.
What is CAYSTON?

CAYSTON is a prescription inhaled antibiotic used to improve breathing symptoms in people with cystic fibrosis (CF) who have a lung infection due to Pseudomonas aeruginosa (Pa). CAYSTON is not a treatment for infections caused by other bacteria or viruses, such as the common cold. CAYSTON is used only with the Altera® Nebulizer System. It is not known if CAYSTON is safe and effective in children under the age of 7 or in patients with FEV1 <25% or >75% predicted.